Every 424B that Indaptus Therapeutics, Inc. (INDP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics, Inc. (INDP) filed an amendment to its at-the-market offering prospectus covering the potential sale of up to $100,000,000 of common stock under an Amended and Restated At-The-Market Offering Agreement with H.C. Wainwright & Co. The amendment’s sole purpose is to fully replace and correct the prior dilution section, fixing clerical errors in the June 30, 2026 net tangible book value calculations and related dilution figures. As of this amendment, no shares have been sold under the program. Based on an assumed sale at $1.14 per share, pro forma net tangible book value would rise from $0.09 to $0.49 per share, implying illustrative dilution of $0.65 per share to new investors.
Indaptus Therapeutics, Inc. (INDP) has established an amended at-the-market equity program to sell up to $100,000,000 of common stock from time to time through or to H.C. Wainwright & Co. under an August 28, 2026 offering agreement, replacing a 2022 ATM. Wainwright will act as sales agent and/or principal and receive a 3.0% commission on gross proceeds. At August 26, 2026, common shares outstanding were 133,242,324, and an illustrative sale of 87,719,298 shares at $1.14 would raise the full capacity.
Net tangible book value at June 30, 2026 was $13.3 million ($0.10 per share); assuming full ATM usage at $1.14, pro forma net tangible book value would be $110.3 million or $0.50 per share, implying dilution of $0.64 to new investors. The company highlights significant risks, including a going-concern explanatory paragraph from its auditor and the absence of any active clinical development programs pending additional financing and strategic review of its Decoy20 immunotherapy platform.
Indaptus Therapeutics, Inc. (INDP) filed a prospectus to register the resale of up to 58,895,000 shares of common stock held by existing investors. The company is not selling any shares and will receive no proceeds; all sale proceeds go to the selling stockholders.
The registered shares comprise 20,000,000 shares issued in a June 2026 private placement and 38,895,000 shares issued upon conversion of Series AAA preferred stock tied to a December 2025 investment and a March 2026 share transfer that resulted in a change of control. These shares equal about 44.2% of the 133,242,324 shares outstanding.
Indaptus is a clinical-stage biotechnology company centered on its Decoy20 immunotherapy platform, but it has no active clinical development programs and has discontinued enrollment in all Decoy20 studies while it evaluates strategic alternatives. Its auditor’s report referenced substantial doubt about the company’s ability to continue as a going concern, and recent ownership and board changes have concentrated control among new stockholders.